Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation

Kathleen M Doss; Madeleine R Heldman; Ajit P Limaye

doi:10.1016/j.idc.2023.10.001

Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation

Infect Dis Clin North Am. 2023 Nov 20:S0891-5520(23)00083-1. doi: 10.1016/j.idc.2023.10.001. Online ahead of print.

Authors

Kathleen M Doss¹, Madeleine R Heldman², Ajit P Limaye³

Affiliations

¹ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
² Division of Infectious Diseases, Department of Medicine, Duke University, Durham, NC, USA.
³ Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: limaye@uw.edu.

PMID: 37989636
PMCID: PMC11102935 (available on 2025-05-20)
DOI: 10.1016/j.idc.2023.10.001

Abstract

The authors summarize recent updates in the prevention and management of cytomegalovirus (CMV) in solid organ transplant (SOT) recipients with a focus on CMV seronegative recipients of organs from seropositive donors (CMV D+/R-) who are at highest risk of CMV infection and disease. They discuss advantages of preemptive therapy for CMV disease prevention in CMV D+/R- liver transplant recipients, letermovir for CMV prophylaxis, and updates in the development of monoclonal antibodies and vaccines as immune-based preventative strategies. They review the roles of maribavir and virus-specific T cells for management of resistant or refractory CMV infection in SOT recipients.

Keywords: Cytomegalovirus (CMV); Letermovir; Maribavir; Monoclonal antibodies; Solid organ transplant; Vaccines; Virus-specific T cells (VST).

Publication types

Review

Grants and funding

U01 AI163090/AI/NIAID NIH HHS/United States